Work

FAITH trial: Feasibility and safety of anlotinib plus benmelstobart in patients with previously immunotherapy treated intermediate-to-advanced hepatocellular carcinoma—Amulticenter, single arm, prospective phase Ⅱ trial.

Year: 2025

Type: article

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e16225

Authors: Yinghao Shen, Xiaoli Zhu, Zhiwei Li, Tao Huang, Yanan Chen, Zhihu Li, Wenlong Zhai, Jian Zhou, Jia Fan, Hui-Chuan Sun

Institutions: Fudan University, Zhongshan Hospital, First Affiliated Hospital of Soochow University, Third Affiliated Hospital of Harbin Medical University, Henan Cancer Hospital, Zhangjiagang First People's Hospital, Zhengzhou University, First Affiliated Hospital of Zhengzhou University

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410813732

FWCI: 0.497

Cites:

Cited by: 1

Related to: 10